ReviewClinical medicine (London, England)2025
Hepatocellular carcinoma (HCC): An update on risk factors, surveillance, diagnosis and treatment strategies.
Review in Clinical medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Synthesis to Mechanism: Biological Evaluation of a p-Toluidine-Based Thiazolidinone-Quinoline VEGFR-2 Candidate Supported by CADD.International journal of molecular sciences · 2026Article
- Cinobufagin as a Potential Intervention Against Liver Cancer-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction-associated steatotic liver disease and its progression to hepatocellular carcinoma.Frontiers in nutrition · 2026Review
- Challenging times in medical education in the era of artificial intelligence can provide opportunities.Clinical medicine (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer is among the fastest-rising causes of cancer-related death in the UK, and the incidence in the UK has increased by almost 50% over the past decade. With increasing incidence of alcohol and metabolic-related liver disease, the rise in cases is expected to continue. While treatable and potentially curable in early stages, it often presents late, owing to the frequently silent nature of liver disease: it is thought that 50% of patients with HCC are unaware of their diagnosis. In the UK, risk of both developing of liver disease and of death from HCC is higher in areas of social deprivation. The recent publication of the NHS 10-year plan and its emphasis on tackling health inequality make this CME article particularly pertinent. With early detection of liver disease and HCC key for favourable outcomes, it is vital that healthcare professionals are aware of the aetiology and surveillance strategies for HCC to optimise liver disease, and to identify disease for curative treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.